These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28163005)

  • 21. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
    Bergmann L
    Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
    [No Abstract]   [Full Text] [Related]  

  • 22. Anastrozole data show continued delay in relapse, but no clear survival advantage.
    Travis K
    J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
    [No Abstract]   [Full Text] [Related]  

  • 23. Theoretical considerations for the ideal aromatase inhibitor.
    Dowsett M
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S39-44; discussion S73-7. PubMed ID: 9797016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A step too far?
    Lancet Oncol; 2005 Oct; 6(10):731. PubMed ID: 16198972
    [No Abstract]   [Full Text] [Related]  

  • 25. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.
    Manquez ME; Shields CL; Karatza EC; Shields JA
    Br J Ophthalmol; 2005 Jun; 89(6):776-7. PubMed ID: 15923523
    [No Abstract]   [Full Text] [Related]  

  • 27. Anastrozole-induced hepatotoxicity.
    Zapata E; Zubiaurre L; Bujanda L; Piérola A
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1233-4. PubMed ID: 17033446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
    Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
    Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations.
    Graham PH
    Expert Opin Pharmacother; 2007 Oct; 8(14):2347-57. PubMed ID: 17927488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity.
    Castiglione-Gertsch M
    Eur J Cancer; 1996 Mar; 32A(3):393-5. PubMed ID: 8814679
    [No Abstract]   [Full Text] [Related]  

  • 31. Anastrozole (Arimidex).
    Wilkinson K
    Clin J Oncol Nurs; 2004 Feb; 8(1):87-8. PubMed ID: 14983769
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
    Nabholtz JM
    Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
    Barros-Oliveira MDC; Costa-Silva DR; Andrade DB; Borges US; Tavares CB; Borges RS; Silva JM; Silva BBD
    Rev Assoc Med Bras (1992); 2017 Apr; 63(4):371-378. PubMed ID: 28614542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
    Johnston SR
    Lancet; 2016 Feb; 387(10021):819-21. PubMed ID: 26686312
    [No Abstract]   [Full Text] [Related]  

  • 35. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
    Nabholtz JM
    Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aromatase inhibitors in early breast-cancer treatment: The story so far.
    Cuzick J
    Breast; 2008 Apr; 17 Suppl 3():S2-8. PubMed ID: 18367396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer.
    Zabolotny BP; Zalai CV; Meterissian SH
    J Surg Oncol; 2005 Apr; 90(1):26-30. PubMed ID: 15786432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
    Mamounas EP; Lembersky B; Jeong JH; Cronin W; Harkins B; Geyer C; Wickerham DL; Paik S; Costantino J; Wolmark N
    Clin Breast Cancer; 2006 Dec; 7(5):416-21. PubMed ID: 17239269
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.